SCHEMBL1285565

SCHEMBL1285565

CCCCSCC[C@@H](N)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
BHMT Q93088 11/20 0.66
BHMT2 Q9H2M3 1/20 0.62
NOS2 P35228 2/20 0.57
NOS1 P29475 2/20 0.57
NOS3 P29474 1/20 0.57
SLC1A2 P43004 2/20 0.50
SLC1A1 P43005 2/20 0.50
SLC1A3 P43003 1/20 0.50
GRIK1 P39086 2/20 0.49
GRIK2 Q13002 2/20 0.49
DDAH1 O94760 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4955426 1.00 BHMT (0.66) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL60520 1.00 BHMT (0.66) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL18832133 0.94 BHMT (0.69) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL17956289 0.93 BHMT (0.58) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL11575012 0.93 BHMT (0.70) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL18832139 0.93 BHMT (0.70) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL18832141 0.93 BHMT (0.70) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL2367840 0.93 BHMT (0.70) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL18832137 0.93 BHMT (0.70) BHMTBHMT2NOS2NOS1NOS3
SCHEMBL2367837 0.93 BHMT (0.70) BHMTBHMT2NOS2NOS1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240065994-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING NICHENAMETLA SAILENDRA NATH (US) 2024-02-29 US claimed
US-20240065994-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING NICHENAMETLA SAILENDRA NATH (US) 2024-02-29 US disclosed
US-9920106-B2 GLP-1 compounds NOVO NORDISK A/S (DK) 2018-03-20 US disclosed
US-9803180-B2 S-adenosylmethionine (SAM) synthase variants for the synthesis of artificial cofactors Leibniz-Institut für Pflanzenbiochemie Stiftung des öffentlichen Rechts (DE) 2017-10-31 US disclosed
US-20170240870-A9 S-ADENOSYLMETHIONINE (SAM) SYNTHASE VARIANTS FOR THE SYNTHESIS OF ARTIFICIAL COFACTORS Leibniz-Institut für Pflanzenbiochemie Stiftung des öffentlichen Rechts (DE) 2017-08-24 US disclosed
EP-3066197-B1 S-ADENOSYLMETHIONINE (SAM) SYNTHASE VARIANTS FOR THE SYNTHESIS OF ARTIFICIAL COFACTORS LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE STIFTUNG DES OFFENTLICHEN RECHTS (DE) 2017-08-16 EP disclosed
US-20160264946-A1 S-ADENOSYLMETHIONINE (SAM) SYNTHASE VARIANTS FOR THE SYNTHESIS OF ARTIFICIAL COFACTORS LEIBNIZ-INSTITUT FÜR PFLANZEN-BIOCHEMIE STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) 2016-09-15 US disclosed
EP-3066197-A1 S-ADENOSYLMETHIONINE (SAM) SYNTHASE VARIANTS FOR THE SYNTHESIS OF ARTIFICIAL COFACTORS Leibniz-Institut Für Pflanzenbiochemie Stiftung Des Offentlichen Rechts (DE) 2016-09-14 EP disclosed
EP-2330126-B1 Protracted exendin-4 compounds NOVO NORDISK AS (DK) 2015-12-23 EP disclosed
EP-1765408-B1 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK AS (DK) 2015-12-09 EP disclosed
WO-2006087354-A2 INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2006-08-24 WO disclosed
EP-1667724-A2 ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES NOVO NORDISK A/S (DK) 2006-06-14 EP disclosed
WO-2006037811-A2 PROTRACTED EXENDIN-4 COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-13 WO disclosed
WO-2006005667-A2 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK A/S (DK) 2006-01-19 WO disclosed
WO-2005093078-A1 GENETICALLY MODIFIED PLANTS AND THEIR APPLICATIONS IN PHYTOREMEDIATION. COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2005-10-06 WO disclosed
WO-2005090583-A1 GENETICALLY MODIFIED PLANTS AND THEIR APPLICATIONS IN PHYTOREMEDIATION. COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2005-09-29 WO disclosed
WO-2005058954-A1 NOVEL GLP-1 COMPOUNDS NOVO NORDISK A/S (DK) 2005-06-30 WO disclosed
WO-2005058958-A2 NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS NOVO NORDISK A/S (DK) 2005-06-30 WO disclosed
WO-2005028516-A2 ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES NOVO NORDISK A/S (DK) 2005-03-31 WO disclosed
US-5439803-A Using label derived from isotopically substituted glucose to measure relative activities of glycolysis and the pentose phosphate pathway THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1995-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240065994-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING HSPA5, TXN2, TXNRD1 BHMT 127/4885BHMT2 207/4885NOS2 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.